Citius Oncology, Inc. (NASDAQ:CTOR) Financings
Financings
| Raise | Date |
|---|---|
| Senior secured term loan with warrants Announced: US$10M–US$25M · Warrants at US$0.9 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Buyers: Avenue Venture Opportunities Fund II, L.P. (up to $25 million senior secured term loan credit facility) Use of proceeds: LYMPHIR commercialization (sales force, market access, medical affairs, supply chain), working capital and general corporate purposes | May 5, 2026 |
| Warrant exercise of exercise of outstanding warrants for common stock Announced: about US$11.5M · US$0.9 a share · Warrants at US$0.9 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: LYMPHIR commercialization (sales force, market access, medical affairs, supply chain), working capital and general corporate purposes | May 5, 2026 |
| Registered direct offering of common stock with unregistered warrants Closed: US$1.09 a share · Warrants at US$1.09 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Support the commercial launch of LYMPHIR, working capital and general corporate purposes | Dec 10, 2025 |
| Private placement of common stock (or pre-funded warrants) and warrants Closed: US$1.09 a share · Warrants at US$1.09 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Support the commercial launch of LYMPHIR, working capital and general corporate purposes | Dec 10, 2025 |
| Registered direct offering of common stock with accompanying unregistered warrants Closed: US$9M raised · US$1.75 a share · ½ warrant at US$1.84 for 66 months · Maxim Group LLC Dealers: Maxim Group LLC (lead) | Sep 10, 2025 |
| Public offering of common stock and warrants Closed: US$9M raised · US$1.32 a share · Warrants at US$1.32 for 60 months · Maxim Group LLC Dealers: Maxim Group LLC (lead) Use of proceeds: Commercialization of LYMPHIR, including license milestone and royalty payments, plus working capital and general corporate purposes | Jul 17, 2025 |